

Aaron P Mitchell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8923306/publications.pdf>

Version: 2024-02-01

36
papers

1,140
citations

758635

12
h-index

433756

31
g-index

36
all docs

36
docs citations

36
times ranked

1736
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 126-132.	2.0	6
2	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine, 2022, 27, 46-54.	1.7	16
3	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 419-426.	3.0	15
4	The Prescription Drug User Fee Act. Medical Care, 2022, Publish Ahead of Print, .	1.1	4
5	Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?. Annals of Internal Medicine, 2021, 174, 353-361.	2.0	124
6	Association between Site-of-Care and the Cost and Modality of Radiotherapy for Prostate Cancer: Analysis of Medicare Beneficiaries from 2015 to 2017. Cancer Investigation, 2021, 39, 1-9.	0.6	1
7	The Role of Physician Professional Networks in Physicians' Receipt of Pharmaceutical and Medical Device Industries' Payments. Journal of General Internal Medicine, 2021, 36, 1858-1866.	1.3	5
8	Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. Oncologist, 2021, 26, 771-778.	1.9	6
9	We Should Treat Financial Toxicity With Curative, Rather Than Palliative, Intent. JCO Oncology Practice, 2021, , OP.21.00540.	1.4	1
10	Industry Payments to Rheumatologists Ought to Be Going Down, Not Up. Arthritis and Rheumatology, 2021, 73, 1951-1953.	2.9	1
11	The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis. Cancers, 2021, 13, 5977.	1.7	1
12	Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014–2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-9.	2.3	5
13	Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. Oncologist, 2020, 25, 46-54.	1.9	7
14	The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating. Pharmacoeconomics, 2020, 38, 737-745.	1.7	5
15	Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care. Journal of the National Cancer Institute, 2020, 112, 1177-1178.	3.0	2
16	Trends in Female Representation on NCCN Guideline Panels. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1084-1086.	2.3	4
17	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1349-1353.	2.3	0
18	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1349-1353.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. <i>Oncologist</i> , 2019, 24, 632-639.	1.9	33
20	Association Between Reimbursement Incentives and Physician Practice in Oncology. <i>JAMA Oncology</i> , 2019, 5, 893.	3.4	28
21	Pharmaceutical Industry Payments and Oncologists's Selection of Targeted Cancer Therapies in Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , 2018, 178, 854.	2.6	44
22	Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 424-432.	0.5	15
23	Anti-EGFR and Anti-VEGF Agents in First-Line Therapy for Advanced Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 257-263.	1.0	0
24	Splenectomy as a Destination: Improving Quality of Care Among Asplenic Veterans Through a Travel Clinic. <i>American Journal of Medicine</i> , 2017, 130, 856-861.	0.6	9
25	Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. <i>JAMA Oncology</i> , 2016, 2, 1628.	3.4	106
26	Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. <i>Journal of Oncology Practice</i> , 2015, 11, 491-497.	2.5	67
27	House Staff Perceptions of How Handoff Quality Influences Code Blue and Rapid Response Team Events. <i>American Journal of Medical Quality</i> , 2015, 30, 292-293.	0.2	0
28	Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e159-e166.	0.9	17
29	Waldenström Macroglobulinemia in Hepatitis C: Case Report and Review of the Current Literature. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-7.	0.2	4
30	Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis. <i>Trials</i> , 2014, 15, 92.	0.7	12
31	Isolation of intraflagellar transport trains. <i>Cytoskeleton</i> , 2013, 70, 439-452.	1.0	8
32	Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States. <i>BMC Research Notes</i> , 2012, 5, 373.	0.6	31
33	Dendritic Cell Populations With Different Concentrations of Lipid Regulate Tolerance and Immunity in Mouse and Human Liver. <i>Gastroenterology</i> , 2012, 143, 1061-1072.	0.6	140
34	A Case of Highly Aggressive Extraskeletal Myxoid Chondrosarcoma. <i>Case Reports in Oncology</i> , 2011, 4, 377-384.	0.3	5
35	In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF- α . <i>Journal of Clinical Investigation</i> , 2009, 119, 3213-25.	3.9	226
36	Function and dynamics of PKD2 in <i>Chlamydomonas reinhardtii</i> flagella. <i>Journal of Cell Biology</i> , 2007, 179, 501-514.	2.3	183